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Abstract
INTRODUCTION—Subjective Cognitive Decline (SCD) manifesting prior to clinical impairment 
could serve as a target population for early intervention trials in Alzheimer’s disease (AD). A 
working group, the Subjective Cognitive Decline Initiative (SCD-I), published SCD research 
criteria in the context of preclinical AD. To successfully apply them, a number of issues regarding 
assessment and implementation of SCD needed to be addressed.
METHODS—Members of the SCD-I met to identify and agree upon topics relevant to SCD 
criteria operationalization in research settings. Initial ideas and recommendations were discussed 
with other SCD-I working group members and modified accordingly.
RESULTS—Topics included SCD inclusion and exclusion criteria, together with the informant’s 
role in defining SCD presence and the impact of demographic factors.
DISCUSSION—Recommendations for the operationalization of SCD in differing research 
settings, with the aim of harmonization of SCD measurement across studies are proposed, to 
enhance comparability and generalizability across studies.
1. INTRODUCTION
Subjective cognitive decline (SCD) is receiving increasing attention as a risk factor for 
incident dementia due to Alzheimer’s disease (AD) (1). SCD manifests prior to the onset of 
clinical impairment (2), and as such could serve as a potential target population for early 
intervention trials (3). Recently, an international working group, The Subjective Cognitive 
Decline Initiative (SCD-I), published research criteria for SCD in the context of preclinical 
AD (4). To successfully apply these criteria, several issues with regard to assessment and 
implementation of SCD need to be addressed.
The categorization of SCD is largely based on self-report by an individual, but also 
potentially by an informant and by the interpretation of this report by the investigator. 
Currently, there is neither a neuropsychological test score nor any accepted self- or observer/
informant scale to classify an individual with SCD. SCD assessment also varies by research 
setting - i.e., epidemiological (5–11) versus memory clinic (12–16). In memory clinics, the 
mere fact that an individual was referred may serve to define the existence of decline. 
Moreover, a detailed clinical history is often obtained in addition to neuropsychological 
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testing, similar to the clinical diagnosis of mild cognitive impairment (MCI) (17–19) and 
dementia (20). This is in contrast to epidemiologic studies, typically comprised of volunteer-
based samples, where the meaning and significance of decline may differ. For multicenter 
research trials and for comparability across studies, however, it is crucial to define research 
criteria for SCD, that promote consistency across sites (4). This implies that subjective 
clinical judgment has to be reduced and objective scales and tests with defined cut-offs are 
needed to provide an operationalized diagnosis (21). This permits a transparent 
understanding and potential replication of the definition of SCD across studies. At the same 
time, it is evident that different studies have different objectives, participant populations, and 
available methods and measures (21–23). Therefore, flexibility of SCD operationalization is 
required to serve the aim of each respective study. The need for flexibility precludes one 
general SCD operationalization for identical application across studies. Furthermore, a 
single approach would limit research because, currently, variability of SCD 
operationalization continues to increase scientific understanding of SCD. Finally, a single 
approach would not be practical with regard to ongoing studies and may not be feasible 
when considering effects of culture and language on SCD reporting.
The aim of this opinion paper is to address core issues in SCD research in more depth and to 
provide recommendations on how to begin operationalizing and implementing SCD criteria 
with the long-term goal of fostering comparability and harmonization of criteria for future 
clinical trial enrollment.
2. METHODS
To achieve the study goals, a writing group was established, comprising 10 members of the 
SCD-I working group. The writing group met at the 2015 Alzheimer’s Association 
International Conference (AAIC) in Washington, DC to identify and agree upon topics 
relevant to the operationalization of SCD criteria in research settings (4). Selected topics 
included those related to SCD inclusion and exclusion criteria, together with the role of the 
informant in defining the presence of SCD and the impact of key demographic factors.
Members of the writing group drafted individual sections of this paper. The manuscript was 
then discussed with other members of the SCD-I working group, and modified accordingly.
Recommendations on the operationalization of SCD in research settings were formulated 
based on theoretical considerations, the existing literature, and expert opinion.
3. RESULTS
In the following section, components of the SCD criteria are discussed in detail with regard 
to their use in research studies.
3.1. Operationalization of the SCD inclusion criteria
Self-experienced persistent decline in cognitive capacity in comparison with a 
previously normal status, and not related to an acute event—SCD in the context 
of preclinical AD refers to the self-perception of a decline in cognitive performance in daily 
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life (4). The term “normal status” refers to the state of subjectively unimpaired (normal) 
cognition. This decline from “normality” to a state with experienced cognitive difficulities 
only refers to the subjective experience of the individual and not to objective 
neuropsychological measures, which are by definition within the normal range. Nonetheless, 
there may be subtle decline from a prior level on objective tests, as demonstrated in studies 
where SCD was preceded by a subtheshold decline in immediate and delayed verbal recall 
(24) and by decline in psychomotor processing speed (25). This supports the idea that SCD 
represents the self-experience of cognitive decline before impairment becomes detectable on 
standardized neuropsychological tests (2, 7, 8, 24, 26).
The criterion also states that SCD is not related to an acute event and is persistent (4). SCD 
is thought to arise from a variety of etiologies, both preclinical AD as well as non-
neurodegenerative conditions. Thus, the course and progression of SCD potentially speaks to 
possible etiology. For individuals with preclinical AD, it is thought that SCD develops 
gradually, corresponding to the gradual disease progression in AD (2, 27). A recent study 
showed that individuals perceived a decline in cognition as early as five years before the 
onset of MCI (28) and in autosomal dominant AD, memory decline precedes MCI by twelve 
years. It has long been postulated that SCD has a duration of 15 years prior to MCI (29) and 
this estimate has been supported by a 9 year prospective study (30, 31). In the SCD position 
paper (4) it was therefore stated that complaints should last longer than six months. On the 
other hand, when complaints persist without progressing to objective cognitive impairment, 
it is possibly less likely that they reflect underlying preclinical AD or other 
neurodegenerative dementias.
Therefore, it is important to document the timeframe of the decline, allowing future studies 
to define the optimal timeframe to identify preclinical AD or other preclinical 
neurodegenerative conditions. This is suggested even though the validity of such 
retrospective estimation is limited.
Although the internal experience of cognitive decline is phenomenologically complex and 
difficult to capture quantitatively (32), most research studies employ quantitative measures 
such as questionnaires. Currently, the field lacks a single, commonly adopted and validated 
approach to the assessment of SCD with great variability in key features of questions posed 
(21, 22). The variability of assessment tools is problematic, because characteristics of 
questionnaire items (e.g., format, phrasing, scaling, and reference points) can influence the 
nature of responses and the reported rates of SCD. In addition, the majority of the 
instruments used to measure SCD focus on memory (21). However, it might be too 
restrictive to limit the SCD assessment to memory, in particular for atypical forms of AD, or 
in the context of non-AD dementias (33). Therefore it is sensible to include other cognitive 
domains (e.g. executive functions, attention, visuospatial functioning, language) in SCD 
assessments (34, 35). For example, recent work by Smart and collaborators demonstrated 
decrements in attention and decision-making, respectively, in persons with SCD as 
compared to healthy older controls (36, 37). Moreover, there has been almost no discussion 
of thresholds or cutoffs for subjective cognitive measures to determine when an individual 
has sufficient experience of decline to be described as having “significant” cognitive 
concerns, making it difficult to compare findings across studies (4). While comprehensive 
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review of the methods used to classify SCD is beyond the scope of the current paper [mainly 
covered by (21)], Table 1 presents a sample of approaches used by a select sample of SCD-I 
Working group members (along with the names and key study features). These data reveal 
considerable variability in every dimension examined such as number of items/
questionnaires, mode of administration, key structural and content features of questionnaire 
items, nature and scaling of response options, approaches to scoring of items, and 
classification criteria. Of note, no two studies used the same method to assess or classify 
SCD and this remains true if one turns to the wider literature. Moreover, while the studies 
reported in Table 1 provided detailed information about their approaches, many other 
published studies fail to report how objective and/or subjective cognition are assessed and 
how test data were used to assign participant groups. Further, while most studies appear to 
take a categorical approach to SCD, a possibility is to consider the potential value of 
continuous approaches that capture features such as frequency and severity of cognitive 
complaints. At present, the field lacks empirical data on the best way to classify SCD to 
maximize the identification of individuals at-risk for AD dementia and to minimize false-
positive identification of individuals not at-risk for AD. Due to practical and conceptual 
barriers with regard to one universal SCD operationalization, with a standard set of SCD 
items, and in order to facilitate communication and comparison of study findings, we 
recommend including the information shown in Table 2 in research reports on SCD.
Recommendations for assessment of inclusion criterion 1: In terms of the items or 
measures that offer the “best” approach to assessment of SCD, there is at present no simple 
recommendation or gold standard questionnaire. In addition, and although there are 
currently no concrete guidelines for which tools are most appropriate for specific research 
contexts, we now offer the following recommendations. We hope that future research will 
clarify this important issue. However, we are in the process of analyzing data from 19 SCD-I 
working group studies, which may result in a short standardized scale (SCD-I basic scale), 
that could be routinely incorporated in future SCD studies. Using such a basic scale, in 
addition to other scales, would be beneficial for fostering future harmonization and cross-
calibration across research studies. For now, we offer the following recommendations (for 
further discussion see (21)), as a first step for SCD harmonization:
• Consult the literature for validated measures developed for a target population 
similar to your own in terms of key demographics and clinical characteristics.
• Consider the research environment, which may impact measurement selection 
decisions. As an example, individuals recruited from a memory clinic (versus a 
volunteer/community sample) may have a higher probability of having 
preclinical AD because they have specific concerns sufficient to prompt a 
medical visit. One suggestion is to inquire about cognitive “concern” or “worry” 
as distinct from “complaints” in community samples to maximize the likelihood 
of identifying the subgroup of individuals with non-normative changes.
• Determine whether to collect self-report data only or, additionally, self- and 
informant-report data. Use of questionnaires that include a study informant is 
recommended (see section 3.3.1), particularly for volunteer/community samples 
where complaints may actually reflect normal age-related changes (i.e., there is a 
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greater probability for false positives in community versus clinical samples). 
Informant report of significant cognitive decline would thus provide convergent 
evidence for complaints reflecting more than normal aging in these settings.
• Select measures with appropriate content coverage for the target population. This 
requires attention to features of questionnaire items including: quality (evidence 
of reliability and validity), content coverage (should tap cognitive domains of 
relevance), face validity (items should be simple and easy to understand and 
should inquire about cognitive issues encountered frequently daily life), cultural 
appropriateness, and specificity (should contain more specific than broadly 
worded items to enhance accuracy of reporting).
• Select measures whose response options correspond to the research question 
(dichotomous scales might be sufficient if the goal is to classify groups, while 
Likert scales are better for quantifying frequency or severity of problems or 
degree of change over time).
• Ensure that reference periods are appropriate for the target population 
(timeframes >1 year could pose difficulties for older adults trying to recall 
specific recent events).
• Include validated measures of mood and anxiety, given their influence on 
cognitive complaints (see section 3.2.1), particularly in volunteer/community 
samples where participants may not receive such measures as part of a routine 
clinical workup. Validated, brief measures with specific clinical cut scores are 
preferable.
• Include information recommended on Table 2 in order to harmonize across SCD 
studies.
Normal performance on standardized cognitive tests, which are used to 
classify mild cognitive impairment (MCI)—In most cases, cognitive impairment 
emerges gradually in the course of neurodegenerative disease (38), and at some point 
reaches a threshold where standardized neuropsychological testing can identify a cognitive 
deficit with a reasonable degree of certainty (17, 39). Conceptually, once this detection 
threshold is met, and major functional deficits are still absent, individuals can be classified 
as having objective cognitive impairment (40). Practically, however, this boundary between 
SCD (hypothetically indicating a pre-MCI stage) and MCI is not a clear line but rather a 
grey zone (41, 42), for several reasons.
First, the precision (reliability) of cognitive tests is inherently limited, and for psychometric 
reasons this is particularly true when short scales or single measures are used to define MCI, 
as is often the case. Second, in the late preclinical period individuals may be able to 
compensate for mild deficits, with variable success (43). Such deficits may be best 
unmasked with highly demanding, sensitive tests (44, 45), but currently such tests are largely 
experimental procedures lacking a normative database (46), limiting broad applicability. 
Third, depending on the research question, researchers have employed either more liberal 
(sensitive) or more restrictive (specific) definitions of impairment for adjudicating MCI. 
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Liberal criteria (e.g. (47)) typically require more than 1 SD deficit in any cognitive domain 
or test (which will necessarily yield false positives MCI “cases” but may also pick up earlier 
disease stages), while stricter criteria typically require a deficit of at least 1.5 SD on specific 
tests, usually memory tests (e.g. the AIBL study – (48)). Partly as a result of these 
measurement issues and operational differences, MCI samples differ widely regarding the 
prevalence of AD biomarkers and clinical progression rates (47).
Given these complexities, the SCD-I agreed not to propose a uniform and “optimal” 
definition of MCI, which would demarcate the upper boundary of SCD. Rather, the 
following levels of objective impairment are considered to exclude a research diagnosis of 
SCD:
• CDR = 0.5 or more (where the CDR score reflects an objective cognitive 
impairment e.g. as assessed with the CDR interview), or a Global Deterioration 
Scale stage 3 or more, or a neuropsychological profile indicating MCI;
• Deficit of more than 1.5 SD on a single test currently used in studies to define 
MCI (e.g. an episodic memory test); or
• Deficit of more than 1.0 SD on two tests within one cognitive domain or of three 
single tests in three different domains (actuarial MCI definition according to Jak 
and Bondi)
It is acknowledged that these different pragmatic “upper boundaries” for cognitive 
impairment will not yield identical results in all cases. Rating scales are valid and well 
established, but rely strongly on self- and informant report and do not assess cognitive 
performance against demographic norms. In specialist settings, the neuropsychological 
profile in an extensive test battery will be judged by experienced clinicians based on 
appropriate norms, and this will likely give a reliable identification of cognitive impairment. 
Reliance on just one single “deviant” test score will result in many false positives (i.e. 
cognitive impairment is assumed despite “true normality”). The actuarial method of Jak and 
Bondi balances reliability and sensitivity and has been shown to reduce the number of 
“misclassified” (i.e. AD-biomarker negative, non-progressing) cases with MCI as defined by 
the ADNI “late MCI” criterion of 1.5 SD deficit in the Wechsler Memory Scale, Logical 
Memory Story A Delayed Recall Story A (49, 50).
A practical advantage of accepting this degree of heterogeneity in defining the cognitive 
normality is that within studies subjects can be classified as either MCI or SCD depending 
on the respective cognitive impairment criterion of this study (avoiding unclassified clinical 
cases). An obvious disadvantage of this heterogeneity is the limited comparability of 
“cognitive normality” between studies, which could become a barrier to progress in SCD 
research.
Whether it will become possible, with psychometrically sound methods, to lower the 
threshold for objective impairment (e.g. to 1.0 SD deficit in a single well-normed, sensitive 
memory task) is an issue for further research. One study addressing this issue found that 
subjects with 1.0–1.5 SD deficit in a Delayed Recall test (termed “early MCI” in ADNI2) 
were indistinguishable from SCD without a cognitive deficit in terms of dementia 
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conversion risk (8). By contrast, using stricter criteria for the definition of MCI, the AIBL 
study has reported that high levels of SCD and evidence of Ab burden in cognitively normal 
older adults at baseline relates to approximately five-fold greater rates of progression to MCI 
or AD (51). Another recent study also found that SCD without cognitive deficit but carriers 
of the APOE ε4 allele showed abnormal changes in amyloid and tau biomarkers, but no 
hypometabolism or medial temporal lobe neurodegeneration, reflecting the at-risk nature of 
the SCD group (52). Taken together, these studies provide promising evidence reflecting the 
at-risk nature of the SCD group. The same cognitive exclusion criteria would also apply to 
define cognitively normal subjects (in the absence of subjective cognitive deficits).
Regarding the distinction with normal aging, cognitive complaints are quite frequent across 
all ages (53). Whether or not these complaints reflect pathological change (in contrast to 
“normal aging”), depends on a number of context features like age of the subject, or help-
seeking. Features known to increase specificity (i.e. the likelihood that SCD indicates 
pathological change due to AD) have been summarized in the SCD-plus criteria (see see 
section 3.3.4 and (4)). In addition, recent qualitative research has begun to identify 
predominant complaint themes in subjects with preclinical AD or MCI, which differ 
somewhat from complaints related to ageing in general. For example, Buckley et al (32) 
found that amyloid-positive healthy subjects, more often than amyloid negative healthy 
subjects, noted a progressive memory, and amyloid-positive subjects with MCI expressed 
more burdensome coping strategies as compared to amyloid-negative MCI subjects. Further 
qualitative research, also involving depressed or anxious (“hypochondriac”) subjects, will be 
needed to further delineate the features indicative SCD due to AD, and to develop 
questionnaires or structured interviews to capture this construct with increased specificity.
Operationalization of SCD also requires attention to basic Activities of Daily Living (ADL) 
and Instrumental Activities of Daily Living (IADL), which should be unimpaired as 
corroborated by an informant. A change in IADL, e.g. in managing finances, may occur 
early in AD, even before significant impairment on cognitive tests (5, 54, 55). When asked 
for examples of SCD, patients, as well as informants, may report subtle difficulties in 
handling complex everyday activities, which earlier had been mastered. In SCD, similar to 
MCI, IADL changes are most likely to take the form of a perceived decrease in the ease and 
efficiency of completing specific tasks rather than a significant loss of functional capacity 
manifest by inability to perform previously accomplished tasks. Clear loss of capacity to 
perform IADLs would be consistent with a diagnosis of dementia. Individuals with MCI 
may show subtle decline in functional capacity without frank impairment. Thus, SCD to 
some degree reflects the aggregated experience of subtle decreases in the ease and efficiency 
of everyday cognitive activities, which may or may not be observable by others. However, 
marked functional ADL/IADL impairments must be excluded as they are indicative of MCI 
or dementia. An operational definition with an established scale (for an overview, see (56)) 
showing absence of significant functional impairment is therefore recommended. This 
approach is identical to the case definition of MCI (57).
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Recommendations for assessment of inclusion criterion 2
• Use standardized validated clinical tests to properly assess cognitive 
performance.
• Define impairment boundaries between SCD and MCI, as a function of the study 
design and objective.
• Confirm preservation of ability to perform IADLs with an appropriately 
validated scale or through interview. Subtle self-perceived decreases in ease and 
efficiency of performing otherwise intact IADLs are consistent with SCD.
3.2. Operationalization of SCD exclusion criteria
Cannot be explained by a psychiatric or neurologic disease (apart from AD), 
medical disorder, medication, or substance use—SCD research criteria list the 
presence of a psychiatric diagnosis (e.g. major depression according to DSM-5, depressive 
episode according to ICD-10) as an exclusion criterion for SCD in the context of preclinical 
AD (4). Individual symptoms of depression or anxiety, or subsyndromal levels of these 
disorders that do not reach the threshold for diagnosis, are common in older adults and not 
considered exclusion criteria. Many psychiatric disorders are associated with significant 
cognitive complaints and even cognitive impairment (6, 55, 58, 59). Thus, including 
individuals with an active psychiatric disorder in studies of SCD in the context of preclinical 
AD would lower the specificity of the study design for AD and inflate the number of false 
positive cases. However, subjective and objective cognitive performance in the context of 
psychiatric disorders and the interaction of AD pathology and psychiatric disorders, such as 
depression, are topics of great interest (60). Some studies may specifically aim to include 
individuals with a psychiatric disorder and subjective and/or objective cognitive impairment 
to study the association with AD pathology. These studies, however, should make their aims 
clear and distinguish their approach from the study of SCD in preclinical AD. The majority 
of SCD studies will focus on early AD identification and prediction of cognitive decline and 
dementia or will aim to identify subjects in the preclinical stage of AD for intervention trials 
(2, 8, 16, 26, 61). These studies will treat a major psychiatric diagnosis as an exclusion 
criterion. Nevertheless, more subtle behavioral or psychological symptoms (not fulfilling 
criteria for a major psychiatric disorder) may be contributing factors in SCD, and therefore 
we recommend incorporation of appropriate scales for psychiatric symptoms in SCD 
studies.
Scales for depression or anxiety can be observer-based (e.g. Hamilton Rating Scale for 
Depression) or self-ratings (e.g. Beck Depression Inventory, BDI-II or Geriatric Depression 
Scale, GDS). Observer-based scales are recommended to measure subthreshold psychiatric 
symptoms. However, in general self-rating scales reflect more subjective well-being and less 
“objective” depressive symptoms. Individuals with SCD may be more introspective and 
more sensitive to perceived changes in their own mental status (62). Thus, they may score 
higher on some items on self-rating depression scales, which may not necessarily reflect 
depressive symptoms. The application of both types of scales (observer-based, self rating) in 
a single study could be of value for detecting potential differences in what those scales 
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measure in SCD and may allow the estimation of the magnitude of difference between both 
approaches.
Notably, depression scales often include items tapping subjective cognition. Individuals with 
SCD will endorse these items, which may not reflect a depressive symptom but rather a 
cognitive complaint related to SCD. This could be the reason for the frequent finding that 
SCD subjects score slightly higher on depression scales than non-SCD cognitively normal 
control subjects without being depressed (6, 63). Some studies remove cognitive items from 
depression scales and create an “adjusted” score (e.g., (64)). On the other hand, subthreshold 
symptoms of depression and anxiety may actually be more frequent in SCD individuals than 
in non-SCD controls (65). For example, Reisberg and colleagues (25) observed more such 
symptoms in SCD participants (Global Deterioration Scale stage 2) than in those without 
subjective cognitive decline (Global Deterioration Scale stage 1 subjects) including 
disturbed sleep, fatigue, weakness, disinterest, and others. In studies with group differences, 
in mood scores, these can be treated as covariates in statistical models, because, since 
covarying for mood and related factors could potentially attenuate or eliminate biomarker 
differences if they share variance with the underlying disorder.
By contrast, an argument against treating subthreshold depression and anxiety symptoms as 
covariates is the possible interaction of these symptoms with SCD, AD pathology, and 
cognitive decline. It has been shown in different samples that particular worries and 
concerns related to SCD are associated with an increased risk of cognitive decline and 
dementia (e.g. (66)). Recently, it has been reported that in amyloid positive healthy elderly, 
symptoms of anxiety predict cognitive decline (67). These and other studies suggest that 
subthreshold symptoms of depression and anxiety should be considered features of interest 
in research. Affective symptoms may be accelerating factors for cognitive decline at the late 
stage of preclinical AD or may even be considered part of the late preclinical AD syndrome 
together with subtle cognitive dysfunction and SCD (on some occasions being the 
explanation for SCD) (68, 69). In this regard, personality traits, which are related to 
increased levels of stress, anxiety and depression have frequently been found to be 
associated with SCD (61, 70). While factors such as openness, conscientiousness, and self-
esteem, correlate with low SCD scores, in particular neuroticism has been associated with 
high SCD reporting (71–73). Neuroticism refers to the tendency of a person to experience 
distressing states such as anxiety, worry, frustration, and loneliness. It is a risk factor for 
mental disorders and a variety of poor health outcomes (74). Neuroticism has also been 
identified as a risk factor for dementia (75). In fact, it has been shown that both, subjects 
with MCI and SCD, who are worried about their memory decline are at higher risk for 
dementia than those just confirming worsening of memory without particular worries (8, 
76). Recently, it was demonstrated that particular worries about memory decline in MCI 
predicts biomarker evidence for AD in CSF (77). In cognitively healthy individuals, an 
association of the SCD report with amyloid deposition has been observed in those 
individuals, who report high on neuroticism (61). Overall, the interaction of SCD, 
neuroticism, AD pathology and risk of dementia seems complex. High stress levels induced 
by neuroticism may accelerate AD pathology and cognitive decline and may also provide 
high sensitivity to intra-individual change such as the development of a neurodegenerative 
disease. Importantly, the data suggest that the notion that SCD is reported in those with high 
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neuroticism and therefore is not related to neurodegeneration or AD seems too simple. In 
particular, in memory clinics a large proportion of individuals report SCD due to non-
neurodegenerative causes. Besides being related to depression or anxiety, these include, but 
are not limited to an attentional focus on normal age associated cognitive decline, with the 
interpretation of being pathologic and increased anxiety about dementia, often in spouses or 
relatives of dementia patients (78). Also normal aging is associated with SCD, however, 
there are a proportion of elderly individuals, who deny cognitive worsening, even on active 
inquiry. In a German sample of over 3327 individuals without dementia over the age of 75 
(average age 80 years, AgeCoDe study), about 30% answered that they did not experience 
memory decline (79). Overall, the causes of SCD reporting in individuals are numerous, 
including age-related factors, personality traits and medical factors, one of which is early 
neurodegeneration. Importantly, in many cases, these causes are not exclusive, but interact. 
Understanding of these interactions may increase the knowledge on the development of 
dementia. In addition, post-mortem studies have shown that neuroticism is associated with 
greater risk of cognitive decline, independent of AD pathology (80). Thus, personality and 
related traits can be of interest in SCD studies as they are a risk factor for symptoms of 
depression and anxiety as well as for cognitive concerns, cognitive decline and dementia 
(75, 81). There is, at present, no reason to exclude any personality profiles from SCD 
studies.
With regard to neurological disorders, medical conditions, medications and substances that 
may impact cognition, it is important to screen for these issues and decide whether they are 
to be treated as exclusionary conditions, given individual study goals. Relevant effects of 
these conditions may be indicated by a temporal association of onset with the onset of SCD, 
although for some disorders past history may also be relevant to understanding cognitive 
functioning and perceived decline. Medications with evidence of impact on cognition and 
brain structure and function, especially in domains similar to AD, warrant particular 
consideration, with drugs having anticholinergic properties being a particularly important 
example (82). A full discussion of potential cognitive effects of medication and substance 
use in older adults at risk for AD is beyond the scope of this report.. Recommendations for 
assessment of exclusion criteria for psychiatric and other comorbidities:
• Exclude individuals with a current major psychiatric diagnosis according to 
ICD-10 or DSM-5 in studies that focus on SCD in preclinical AD, unless the 
studies specifically focus on the association of SCD with preclinical AD in the 
context of a psychiatric disorder.
• Carefully assess whether a history of major psychiatric disorders may impact 
cognition and especially self-perception of cognitive functioning, and hence may 
be related to SCD. If so, exclude these conditions.
• Include measures of depression and anxiety in SCD studies. Analyze any items 
in those scales that focus on cognition and consider creating adjusted scores. 
Potentially include the mood scale scores in statistical models. We also 
recommend the application of cut-offs on mood scales to help identify subjects 
who should potentially be excluded based on fulfilling diagnostic criteria for a 
psychiatric disorders.
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• Carefully consider as exclusion criteria and report neurological or medical 
conditions, medication and substance use, which may be linked to SCD.
3.3. Additional factors of relevance in SCD research
The role of the study partner /informant—Although confirmation of decline by the 
informant is not necessary according to the SCD definition, the initial subjective cognitive 
decline initiative (SCD-I) consensus paper noted that confirmation by knowledgeable others 
was a feature that increased the risk of AD dementia (4). As consistently reported in the 
literature, the progression of AD and other dementias is associated with poorer insight into 
cognitive deficits (12), and informant report is of increasing value and relevance along the 
disease continuum (83, 84). The progression of these changes from both the subject 
perspective and the informant perspective in terms of memory, emotional changes and 
functional changes from no cognitive decline, to SCD, to MCI, to mild, moderate and 
moderately severe dementia was described in a study by Reisberg and colleagues (85). In 
another study using National Alzheimer’s Coordinating Center data, Gifford and colleagues 
found that self and informant reports were independently and additively predictive of future 
risk of dementia (84). In this study, the odds for predicting a poor cognitive trajectory were 
approximately two-fold for self and informant reports separately, but increased to an odds 
ratio of 4 when considered together.
Informant report has been associated with the risk for developing AD in SCD in community 
elders (9, 86, 87). There is also evidence that the composite of both self and informant report 
accurately predicts hippocampal atrophy (64) and longitudinal decline at the earliest stages 
of disease, possibly better than self or partner report alone (5, 84). When examining the 
association between self- and informant-reported everyday function and brain volumes 
across the disease spectrum, the strength of the associations tended to be higher for the 
informant ratings than for self-report (10). Moreover, a recent study showed that informants’ 
ratings of the subjective cognitive decline questionnaire (SCD-Q) were significantly higher 
in preclinical AD compared to elderly controls, presenting, by contrast, no significant 
differences in the self-rating scores were obtained with the SCD-Q (88). In the same study, 
the relation of the SCD-Q score with AD cerebrospinal fluid (CSF) biomarker levels was 
explored in a sample including SCD subjects and cognitively impaired subjects, showing 
that informant ratings of SCD-Q correlated significantly with Aβ42 and tau levels, while 
self-rating did not correlate with any AD biomarker (88). Although the number of studies 
reporting the relation between CSF AD biomarkers and informant ratings of SCD is low, 
they seem to point in the same direction. Rueda and colleagues (10) found that in a sample 
constituted by cognitively normal and impaired subjects, informant ratings of SCD 
significantly correlated with Aβ42 and ptau CSF levels and a smaller hippocampal volume. 
Similarly, Okonkwo and colleagues found that CSF Aβ42, tau and ptau levels correlated 
with informant report of functional decline in cognitively normal elders and in a MCI group 
(89). By contrast, very early on in the disease course, self report may better track disease 
progression, while later on informant report may supercededs self report (83, 90). Taken 
together, the literature strongly suggests that both the informant and self report can provide 
both synergistic and individually meaningful information along the AD trajectory, and as 
such, both should be measured in future studies. In that regard, informant report reflects 
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potentially a slightly more progressed state of decline, where cognitive dysfunction becomes 
evident for an observer, while earlier, full compensation is still possible and cognitive 
dysfunction is only noted by the individual him- or herself.
In summary, current evidence suggests that in cognitively normal SCD subjects, informant 
reports have prognostic value and may correlate better with cognitive performance and with 
AD biomarkers than self-report alone. Therefore, when possible assessment of SCD should 
be performed with questionnaires that also include an informant report.
Assessment of SCD longitudinally—As has been noted, tools to identify individuals 
with SCD vary considerably across studies and can range from a single question about 
memory decline to exhaustive questionnaires that tap multiple cognitive domains. While 
using a brief measure to classify SCD individuals a priori may be appropriate, this strategy is 
less likely to be useful in tracking the evolution of SCD longitudinally. Several studies have 
investigated longitudinal change in SCD and its correspondence to cognitive outcomes (5, 
25, 91, 92). The relation between cognitive performance and subjective decline is further 
complicated when self and informant reported measures of SCD are introduced. Very early 
on the disease course, self-report may better track disease progression, while later on 
informant report may supersede self report (83, 90). In addition, self and informant reports 
although may initially align, they diverge when objective cognitive impairment is present. In 
fact, MCI subjects associated with greater informant concern, present poorer cognitive 
performance, exposing a changing insight with advancing memory impairment (83). These 
findings suggest a dynamic relationship between subjective and objective measures along the 
early disease trajectory, such that there are points where they are more and less associated, 
with the clearest divergence by the stage of clinical impairment.
In the future, change in SCD may be one way of assessing longitudinal functional benefit in 
secondary prevention trials (5) but there will need to a consensus on which particular 
measure(s) are most effective in capturing the full realm of subjective cognitive changes 
early in the disease. Most research to date has focused on sensitive measures of cognitive 
concerns for the purposes of early detection rather than as dynamic outcome markers 
optimized for measuring longitudinal change, though both applications are important.
Demographic issues that may be of relevance in SCD research—Factors such as 
demographics, knowledge of genetic risk, and medical issues may impact SCD. Concerns 
about memory typically increase as individuals grow older (93, 94), and the types of 
complaints may vary by age range, perhaps due to the fact that younger and older 
individuals assume different reasons to explain their memory lapses (95). Because SCD 
related to AD is thought to occur before the MCI stage at the late preclinical phase, the 
likelihood that SCD is associated with AD increases with age. Within older individuals, 
however, there is evidence to suggest that SCD becomes less predictive of dementia risk in 
80 year olds compared to persons in their 70s, as memory complaints become more 
ubiquitous and less specific as individuals age (94). Thus, there may be in optimal age range 
in which SCD is useful for predicting risk for AD progression.
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Several studies indicate that education attainment level may modify the relationship between 
SCD and risk for AD. While less education has been associated with greater overall memory 
concerns in some studies (93, 96), paradoxically the role of SCD in predicting longitudinal 
cognitive decline may be stronger in the high education group (97, 98). One possibility is 
that individuals with lower cognitive reserve report greater memory complaints that reflect 
longstanding difficulties, but SCD in more highly educated individuals may reflect more 
recent changes due to underlying pathology. Also, highly educated subjects can sustain a 
greater degree of pathology and still perform within normal limits on cognitive tests due to 
greater cognitive reserve (99). A recent FDG-PET study showed, that cognitively normal 
subjects with emerging amyloid pathology showed stronger temporal and parietal lobe FDG-
PET hypometabolism at higher levels of education (100). Thus, SCD individuals with higher 
cognitive reserve may perceive cognitive changes at relatively later stages in the 
neuropathological disease process where cognitive decline is imminent. Further studies are 
needed, but SCD in individuals with higher education may be particularly sensitive as an 
early indicator of AD risk.
Findings on the relationship between SCD and sex differences are equivocal. Some studies 
have reported greater memory complaints in women compared to men (96, 101), but the 
reverse has also been shown (94), while others have found no impact (6, 102). Presently, it is 
unclear if sex modifies the relationship between risk for AD and SCD.
Few studies have investigated SCD across race and ethnicity. In one study of African 
Americans, SCD was found to be associated primarily with factors of psychological well-
being, such as higher levels of perceived stress, rather than longitudinal cognitive decline 
(103). In another study that directly compared African Americans and Caucasians, African 
Americans were less likely to report memory complaints, despite greater evidence of 
objective cognitive decline longitudinally (104). Further work is needed to determine 
whether SCD may manifest differently in different racial or ethnic groups. A family history 
or knowledge about increased risk for developing AD may impact report of SCD. In one 
study, older adults with a positive family history of AD rated their memory functioning 
lower than those without a family history (105). Knowledge of APOE gene status has also 
been shown to impact subjective report of memory. Specifically, individuals who were 
known to have APOE-ε4 judged their memory more harshly than those who were APOE-ε4 
without knowledge of their genotype (106). By contrast, individuals who knew that they 
were APOE-ε4 negative judged their memory more positively than those who were blinded 
APOE-ε4 negative. Increasingly, clinically normal individuals may now have the 
opportunity to know their amyloid status if enrolled in clinical trials in certain countries 
(107, 108), although human research ethics boards still restrict this information in most 
settings. Understanding how knowledge of amyloid status may impact self-perceived 
memory will be important as data become available.
Finally, it is not surprising that other non-AD medical issues could underlie SCD. For 
example, poor overall physical health (9), greater white matter hyperintensities (109), and 
Parkinson’s disease (110) among others, have all been shown to be related to higher report 
of SCD. Thus, SCD in individuals with significant medical issues, particularly those that 
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impact cognition, should be interpreted carefully, as it may be hard to disentangle the 
etiology of memory complaints in these cases.
Specific assessment of SCD plus criteria—Other relevant factors in SCD research 
are those that may be associated to increased likelihood of preclinical AD. Indeed, in the 
consensus paper on SCD in preclinical AD (4), a list of SCD-features was presented, which, 
according to the current standard of the literature are associated with an increased likelihood 
for preclinical AD (SCD-plus). These features are: (1) subjective decline in memory, rather 
than other domains of cognition, (2) onset of SCD within the last 5 years, (3) age at onset of 
SCD > 60 years, (4) paricular concerns (worries) associated with SCD, (5) feeling of worse 
performance than others of the same age group, (6) confirmation of perceived cognitive 
decline by an informant, and (7) presence of the APOE ε4 genotype. Although, initial efforts 
to validate the SCD plus criteria have started (111), they may still be subject to change as 
research progresses.
Recommendations on additional relevant factors
• Assessment of SCD should include both self- and informant report 
questionnaires when possible.
• Special attention should be applied when measuring SCD in people with greater 
cognitive reserve. Interpreting SCD measures in the context of cognitive reserve, 
such as by recording education attainment levels, appears warranted.
• Exercise caution in interpreting SCD with individuals who are aware of their 
amyloid status, as this may impact their self perceived cognition.
• The presence of multiple medical issues in SCD study participants should be 
collected and interpretation of SCD due to AD should be made with caution.
• To integrate SCD-plus assessment in most or all SCD studies to extend the 
empirical database on SCD plus items to validate or reject them as being 
associated with preclinical AD in the future.
4. DISCUSSION
In this paper, we propose recommendations for the operationalization of SCD in differing 
research settings, with the aim of harmonization of SCD measurement across studies. This is 
challenging, however, and a gold standard for the investigation of SCD is not yet available. 
Nonetheless, we recommend a number of topics that need to be clearly described in any 
paper addressing SCD to enhance comparability and generalizability across studies. This 
may reduce inconsistencies that are currently evidenced in the literature.
Regarding the assessment of SCD, defined as self-experienced persistent decline in cognitive 
capacity, rather than an operational definition we recommend a set of guidelines to start 
harmonizing SCD detection and assessment. We also suggest the type of information to be 
reported in each SCD study, to ensure consistency and learning over time. Assessing the 
presence of SCD based on self-report data only or self- and informant-report data yields 
different results and outcomes. The evidence provided above suggests that both are of value 
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in SCD participants, self reports possibly being more critical at earlier stages and informant 
reports having a greater prognostic value and correlating better with cognitive performance 
and AD biomarkers. Therefore, we recommend collecting how SCD has been assessed and 
when feasible assessing SCD with questionnaires that also include informant report data. In 
order to assess and quantify SCD, validated measures should be employed. These measures 
should be suitable for the target population, in terms of demographics and clinical 
characteristics, and with appropriate content coverage, in terms of quality, face validity, 
cultural appropriateness and specificity. Currently, SCD questionnaire items present a 
limited overlap with 75% of the items used uniquely in a single study (21). Therefore, in 
order to advance the field, harmonization and pooling of international SCD data is necessary. 
Future studies should also strive to use a short set of identical questions, not only to define 
the presence of SCD but also to measure it. In this sense, dichotomous questionnaires might 
be sufficient if the goal is to classify groups, while Likert scales might be more benefitial for 
quantifying frequency or severity of problems, or degree to which changes occur over time. 
Using a single, standardized questionnaire across studies does not seem feasible in the near 
future, but we should now aim to implement questionnaires with comparable face validity 
going forward. For the vast majority of SCD instruments, there is little evidence for 
psychometric quality, and a majority are newly developed within the past decade. This 
highlights the need for cross-validation of these measures. Self-report measures will need to 
be psychometrically evaluated, showing adequate internal consistency, content and construct 
validity, test-retest reliability, and differences between subgroups of interest [see (112)]. 
Item response theory might offer a method to select qualitative items, as currently being 
tested by the SCD-I in the ‘item analysis project’.
Regarding the timeframe of the persistent decline in cognitive capacity relative to a prior 
baseline, it is important to collect information about how long the participant has been 
experiencing the decline. As stated in Jessen et al. (4) shorter periods, may have greater 
relations to preclinical AD. It is equally important to ensure that reference periods are 
appropriate for the target population because asking older adults to recall specific recent 
events from periods of time longer than one year can yield non-reliable results. 
Establishment of clear criteria for what constitutes “significant” or “meaningful” subjective 
concern is challenging. In particular, there is an unmet need to define “SCD-positivity” and 
to harmonize methods for its determination. Currently, it is uncertain whether within the 
continuum of subjective perception of decline there is a threshold that could be defined on 
the basis of predictive value for subsequent cognitive impairment. It also remains unknown 
whether this threshold should be adjusted for age, gender, or education. When sound 
approaches to SCD classification are met, significant improvements will be made in 
characterizing the specific cognitive phenotypes of SCD. A major issue regarding 
operationalization is determining what normal cognition means in the context of SCD. The 
suggested approach is defining the impairment threshold for normality, in other words 
defining what will constitute the beginning of MCI from a normative perspective hence the 
end of SCD stage (65). Unfortunately, there is no operational consensus in the field on how 
to measure objective cognitive impairment and what threshold of impairment is required for 
an MCI diagnosis. In part, this is due to the fact that, depending on the research question, a 
more liberal (sensitive) or a more restrictive (specific) definition can be chosen. Liberal 
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criteria for MCI typically set the impairment threshold at - 1 SD magnitude deficit in any 
cognitive domain or test (which will necessarily yield false positives, but may identify 
earlier disease stages), while stricter criteria typically require a deficit of at least 1.5 SD in 
specific tests, usually memory tests. Using strict criteria (47) to define MCI would 
necessarily suggest that some patients with minimal/subtle cognitive impairment may be 
considered SCD; on the other hand using liberal criteria will exclude people from the SCD 
group, who in some cases may have questionable MCI. We acknowledge that as a function 
of the research question, either approach may be appropriate, so rather than suggesting a 
definite operationalization approach we recommend using standardized validated tests, 
specifying the upper cognitive impairment boundaries used in the study, and confirming 
preservation of iADLs with a proper validated scale. Future work comparing different SCD 
studies with a harmonized methodology, although with different boundaries, will be of value 
to define the optimal boundaries between SCD and MCI to define SCD prognosis and the 
sensitivity and specificity of the different approaches to detect the presence of preclinical 
AD. It is not uncommon to observe anxiety and depresive symptoms among SCD 
particpants. In fact, self reported measures of SCD correlate more with personality traits 
than with AD biomarkers, being the opposite with proxy-related questionnaires (61, 90). 
Neverthelees, patients at early stages of AD also present emotional, psychological and mild 
behavioral disturances (113). Excluding individuals based on the presence of mild 
psychiatric symptoms is therefore not recommended.
Operationalization and harmonization of SCD is beginning. This paper represents a starting 
approach to begin harmonizing and operationalizing the SCD criteria in order to move the 
field forward. With more uniformity of ascertainment of SCD we will be better positioned to 
understand the generators of SCD, heterogeneity of outcomes, and the optimal measures for 
early detection and as dynamic outcome metrics.
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1. Systematic review: The authors reviewed the literature using traditional 
sources. Studies investigating subjective cognitive decline (SCD) are 
appropriately cited throughout the manuscript.
2. Interpretation: This opinion paper addresses core issues in SCD research in 
more depth and provides recommendations on how to begin operationalizing 
and implementing SCD criteria with the long-term goal of fostering 
comparability and harmonization of research studies. Main topics include 
those related to SCD inclusion and exclusion criteria, the role of the informant 
in defining the presence of SCD and the impact of key demographic factors
3. Future directions: Operationalization and harmonization of SCD is beginning. 
This paper represents a consensus approach to harmonize and operationalize 
SCD criteria to move the field forward. With more uniformity of 
ascertainment of SCD we will be better positioned to understand the 
generators of SCD, heterogeneity of outcomes, and the optimal measures for 
early detection and as dynamic outcome metrics.
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TABLE 1
Approaches to Classifying SCD among a Sample of Subjective Cognitive Decline Initiative (SCD-I) Working 


























Subjective cognition: Assessed by the question: Do
you feel like your memory is becoming worse?
Response options include no; yes, but this does not
worry me; and yes, this worries me. Participants
reporting a memory decline with worry are rated as
having SCD. In an alternative classification
approach, participants reporting a memory decline
without associated concerns (worries) are rated as
SCD-C and those reporting a memory decline with
associated concerns are rated as SCD+C.
Objective cognition: Performed less than 1.0 SD
below the normative mean on the CERAD verbal
memory delayed recall performance [Jessen-2014]
or performed less than 1.0 SD below the normative
domain scores on the cognitive assessment of the












Subjective cognition: Assessed by the question: Do
you have difficulties with your memory, yes or no?.
Objective cognition: Scores of MMSE >27/30,
normal performance on Logical Memory test, no
evidence of significant difficulty on standardized
neuropsychological tests of memory, language,
attention, executive functioning, and psychomotor
speed, and a CDR score of less than 0.5. Additional
criteria: no medical illness likely to impair cognitive
function, no informant or personal history
suggestive of impaired cognitive function, and no
medications or substances that could affect
cognition.
Alzheimer’s Disease
Center Clinical Core and






Subjective cognition: Subjective complaints of
cognitive deficit on two clinician interview
measures: Global Deterioration Scale for age-
associated cognitive decline and dementia which
cites the SCD complaints, i.e, memory for names of
people and placement of common objects,
subsequently found to be represented in the
greatest percentage of measures (56 % each)
surveyed (n= 34 measures) and the Brief Cognitive
Rating Scale, which assesses the presence of
subjective impairments in concentration and
calculation, memory, orientation, and functional
abilities.
Objective cognition: No objective evidence of
memory deficit on clinical interview. Performed
normally on the objective portion of the Brief
Cognitive Rating Scale, which includes tests of
concentration and calculation, memory,
orientation, and functioning abilities, carried out
during the clinical interview. Additional criteria: No
objective deficit in employment or social situations.














Subjective cognition: Assessed with a Cognitive
Complaint Index (CCI) ranging from 0 to 100, based
on items endorsed across measures including:
Memory Self-Rating Questionnaire, Activities of
Daily Living Rating Scale- self and informant ,
Informant Questionnaire on Cognitive Decline in
the Elderly short form- self and informant, cognitive
































items from the Geriatric Depression Scale, and
cognitive items from the Memory and Aging
Telephone Screen. Presence of significant cognitive
complaints required endorsement of approximately
>20% of complaints on the CCI or complaints
deemed significant by clinical consensus. Additional
criteria: normal activities of daily living and no
depression or psychiatric disorder that would
account for the cognitive complaints. Diagnoses
made by multidisciplinary consensus.
Objective cognition: Scores within 1.5 standard
deviations of the mean established for age- and
education-matched controls on standardized
neuropsychological testing of memory, attention,
executive function, language, spatial ability, general











Subjective cognition: Self-reported cognitive
complaint + 10-item cognitive complaint
questionnaire. Clinician established that SCD was
not caused by medication, mood, or other medical
conditions. Diagnoses made by multidisciplinary
consensus.
Objective cognition: Performed in the normal range
for age and education on standardized
neuropsychological tests of global cognition, verbal
and visual episodic memory, visuospatial
functioning, language, verbal fluency, working
memory, and executive functions.
INSIGHT-AD; Inserm
and the city of Paris
public hospital system
(AP-HP) at the Institute
of Memory and
Alzheimer’s Disease









Cognitive complaint assessment (Visual Analogic
Scale), Questionnaires of Memory complaint.
Questionnaire of Conversion (QOC).
The QOC was developed as a new tool to detect the
early signs that may be associated with the onset of
a clinical AD at a prodromal stage. It was especially
designed to follow-up for the “asymptomatic-at-
risk” population of the INSIGHT cohort. The QOC
informant-based questionnaire consists of 12
‘Yes/No’ questions and covers memory,
behavioural, mood, motivation and attention items.
The questions are given to the respondent on the
paper for self–administration or can be read aloud
to the respondent either in person or over the
phone. The total score (positive answers) is
recorded.
Objective cognition:
Performed in the normal range for age and
education on standardized neuropsychological tests







Subjective cognition: By definition as patients were
referred by their GP to the memory clinic based on
cognitive complaints.
Objective cognition: Performed in the normal range












Subjective cognition: Assessed with the Memory
Failures Everyday (MFE-30)[Lozoya-Delgado 2012];
Scores ≥8 considered significant. Additional criteria:
no depression, anxiety, psychiatric disorder, or
systemic conditions or medications to account for
the complaints.
Objective cognition: Performed in the normal range
for age and education on the standardized
Fundació ACE Neuropsychological Battery.








































Subjective cognition: SCD-Q, which include
“MyCog” (self-reported cognitive complaint) and
“TheirCog” (informant’s ratings).
Objective cognition: Performed in the normal range
for age and education on standardized
neuropsychological tests of global cognition, verbal
and visual episodic memory, visuospatial
functioning, language, verbal fluency, working
memory, and executive functions.





















Molinuevo et al. Page 29
TABLE 2
Information recommended to be included in research reports on SCD:
1 Measurement approach:
• Research environment (e.g., memory clinic, volunteer sample, population-based cohort)
• Names of measures (where relevant) and information about their psychometric properties
• Respondent category (e.g., self, informant, clinician, self- and informant)
• Administration mode (e.g., paper-and-pencil, spontaneous report, phone interview)
• Timeframe and reference group (e.g., comparison to age-peers, comparison to oneself at an early time point, 
compared to previously normal state)
• Domains tapped (e.g., memory only; memory, language, attention)
2 Defined cutoffs on subjective report measures, or other approach used, with explanation for how cutoffs were derived to quantify 
level of subjective cognitive impairment (including information about normative comparisons and any demographic adjustments)
3 Defined cutoffs on objective report measures, or other approach used, with explanation for how cutoffs were derived to quantify 
level of objective cognitive impairment (including information about normative comparisons and any demographic adjustments)
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